Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Protalix BioTherapeutics (PLX) Accumulated Depreciation & Amortization (2016 - 2025)

Protalix BioTherapeutics (PLX) has 15 years of Accumulated Depreciation & Amortization data on record, last reported at $35.7 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization rose 3.03% year-over-year to $35.7 million; the TTM value through Dec 2024 reached $35.7 million, up 3.03%, while the annual FY2024 figure was $35.7 million, 3.03% up from the prior year.
  • Accumulated Depreciation & Amortization reached $35.7 million in Q4 2024 per PLX's latest filing, up from $34.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $35.7 million in Q4 2024 and bottomed at $31.9 million in Q4 2020.
  • Average Accumulated Depreciation & Amortization over 5 years is $33.8 million, with a median of $33.7 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: rose 3.97% in 2020, then increased 2.6% in 2021.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $31.9 million in 2020, then rose by 2.6% to $32.8 million in 2021, then increased by 2.85% to $33.7 million in 2022, then increased by 2.97% to $34.7 million in 2023, then rose by 3.03% to $35.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $35.7 million in Q4 2024, $34.7 million in Q4 2023, and $33.7 million in Q4 2022.